Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC).
EZH2
NSCLC
T cell differentiation
Transcription factors
YY1
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
22 May 2023
22 May 2023
Historique:
received:
22
01
2023
accepted:
11
05
2023
medline:
24
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Non-Small Cell Lung Cancer (NSCLC) is the leading cause of death in all countries alike. In the current study, we have found out that Histone H3Lys4trimethylation is abnormal on YY1 in CD4
Identifiants
pubmed: 37212947
doi: 10.1007/s12032-023-02053-2
pii: 10.1007/s12032-023-02053-2
doi:
Substances chimiques
Transcription Factors
0
Histones
0
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
EZH2 protein, human
EC 2.1.1.43
YY1 protein, human
0
YY1 Transcription Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185Subventions
Organisme : Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India
ID : ECR/2016/000965
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Chen B, Zeng C, Ye Y, et al. Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer. J Cell Commun Signal. 2018;12:423–32. https://doi.org/10.1007/s12079-017-0418-2 .
doi: 10.1007/s12079-017-0418-2
pubmed: 29086202
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. https://doi.org/10.21037/tlcr.2016.06.07 .
doi: 10.21037/tlcr.2016.06.07
pubmed: 27413711
pmcid: 4931124
Sharma S, Kelly T, Jones P. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27–36. https://doi.org/10.1093/carcin/bgp220 .
doi: 10.1093/carcin/bgp220
pubmed: 19752007
pmcid: 2802667
Pandya P, Murray M, Pollok K, Renbarger J. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res. 2016;4273943:1–13. https://doi.org/10.1155/2016/4273943 .
doi: 10.1155/2016/4273943
Yu J, et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007;12(5):419–31. https://doi.org/10.1016/j.ccr.2007.10.016 .
doi: 10.1016/j.ccr.2007.10.016
pubmed: 17996646
Cao Q, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27(58):7274–84. https://doi.org/10.1038/onc.2008.333 .
doi: 10.1038/onc.2008.333
pubmed: 18806826
pmcid: 2690514
Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9. https://doi.org/10.1038/nature01042 .
doi: 10.1038/nature01042
pubmed: 12374981
Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood. 2010;115(15):3098–108. https://doi.org/10.1182/blood-2009-07-233858 .
doi: 10.1182/blood-2009-07-233858
pubmed: 20190193
pmcid: 2858468
Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007;21(5):525–30. https://doi.org/10.1101/gad.415507 .
doi: 10.1101/gad.415507
pubmed: 17344414
pmcid: 1820894
Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara- Konishi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012;78(2):138–43. https://doi.org/10.1016/j.lungcan.2012.08.003 .
doi: 10.1016/j.lungcan.2012.08.003
pubmed: 22925699
Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 2010;17(5):801–10. https://doi.org/10.1038/cdd.2009.162 .
doi: 10.1038/cdd.2009.162
pubmed: 19893569
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27:7274–84.
doi: 10.1038/onc.2008.333
pubmed: 18806826
pmcid: 2690514
Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates Ecadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 2008;99(4):738–46. https://doi.org/10.1111/j.1349-7006.2008.00743.x .
doi: 10.1111/j.1349-7006.2008.00743.x
pubmed: 18377425
Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol. 2011;26(1):19–27. https://doi.org/10.1111/j.1440-1746.2010.06447.x .
doi: 10.1111/j.1440-1746.2010.06447.x
pubmed: 21175789
Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106(2):243–7. https://doi.org/10.1038/bjc.2011.551 .
doi: 10.1038/bjc.2011.551
pubmed: 22187039
Li H, Bitler BG, Vathipadiekal V, et al. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genomewide approaches. Cancer Prev Res. 2012;5(3):484–91. https://doi.org/10.1158/1940-6207.CAPR-11-0414 .
doi: 10.1158/1940-6207.CAPR-11-0414
Karantanos T, Christofides A, Bardhan K, Li L, Boussiotis V. Regulation of T cell differentiation and function by EZH2. Front Immunol. 2016;7:346. https://doi.org/10.3389/fimmu.2016.00172 .
doi: 10.3389/fimmu.2016.00172
pubmed: 27648006
pmcid: 5022364
Tumes D, Onodera A, Suzuki A, Shinoda K, Endo Y, Iwamura C, Hosokawa H, Koseki H, Tokoyoda K, Suzuki Y, Motohashi S, Nakayama T. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity. 2013;39(5):819–32. https://doi.org/10.1016/j.immuni.2013.09.012 .
doi: 10.1016/j.immuni.2013.09.012
pubmed: 24238339
Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochem Biophys Acta. 1997;1332(2):F49–66. https://doi.org/10.1016/S0304-419X(96)00044-3 .
doi: 10.1016/S0304-419X(96)00044-3
pubmed: 9141463
Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene. 1999;236(2):197–208. https://doi.org/10.1016/S0378-1119(99)00261-9 .
doi: 10.1016/S0378-1119(99)00261-9
pubmed: 10452940
Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25(8):1125–42. https://doi.org/10.1038/sj.onc.1209080 .
doi: 10.1038/sj.onc.1209080
pubmed: 16314846
Wu S, Hu YC, Liu H, Shi Y. Loss of YY1 impacts the heterochromatic state and meiotic double-strand breaks during mouse spermatogenesis. Mol Cell Biol. 2009;29(23):6245–56. https://doi.org/10.1128/MCB.00679-09 .
doi: 10.1128/MCB.00679-09
pubmed: 19786570
pmcid: 2786691
Hwang S, Kim Y, Lee S, Jang S, Kim M, Koh B, Lee W, Kim J, Souabni A, Busslinger M, Lee G. Transcription factor YY1 is essential for regulation of the Th2 cytokine locus and for Th2 cell differentiation. Proc Natl Acad Sci. 2012;110(1):276–81. https://doi.org/10.1073/pnas.1214682110 .
doi: 10.1073/pnas.1214682110
pubmed: 23248301
pmcid: 3538243
Tsang D, Wu W, Kang W, Lee Y, Wu F, Yu Z, Xiong L, Chan A, Tong J, Yang W, Li M, Lau S, Li X, Lee S, Yang Y, Lai P, Yu D, Xu G, Lo K, Chan M, Wang H, Lee T, Yu J, Wong N, Yip K, To K, Cheng A. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma. J Pathol. 2016;238(5):651–64. https://doi.org/10.1002/path.4688 .
doi: 10.1002/path.4688
pubmed: 26800240
Pal R, Rakshit S, Shanmugam G, Paul N, Bhattacharya D, Chatterjee A, Singh A, George M, Sarkar K. Involvement of xeroderma pigmentosum complementation group G (XPG) in epigenetic regulation of T-helper (TH) cell differentiation during breast cancer. Immunobiology. 2022. https://doi.org/10.1016/j.imbio.2022.152259 .
doi: 10.1016/j.imbio.2022.152259
pubmed: 36037675
Taylor M, Sadhukhan S, Kottangada P, Ramgopal A, Sarkar K, D’Silva S, Selvakumar A, Candotti F, Vyas Y. Nuclear role of WASp in the pathogenesis of dysregulated TH1 immunity in human Wiskott–Aldrich syndrome. Sci Transl Med. 2010;2(37):3744–3744. https://doi.org/10.1126/scitranslmed.3000813 .
doi: 10.1126/scitranslmed.3000813
Sarkar K, Sadhukhan S, Han S, Vyas Y. Disruption of hSWI/SNF complexes in T cells by WAS mutations distinguishes X-linked thrombocytopenia from Wiskott–Aldrich syndrome. Blood. 2014;124(23):3409–19. https://doi.org/10.1182/blood-2014-07-587642 .
doi: 10.1182/blood-2014-07-587642
pubmed: 25253772
pmcid: 4246038
Sarkar K, Han S, Wen K, Ochs H, Dupré L, Seidman M, Vyas Y. R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott–Aldrich syndrome. J Allergy Clin Immunol. 2018;142(1):219–34. https://doi.org/10.1016/j.jaci.2017.11.023 .
doi: 10.1016/j.jaci.2017.11.023
pubmed: 29248492
Sarkar K, Sadhukhan S, Han S, Vyas Y. SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF- B response genes in T cells. Blood. 2015;126(14):1670–82. https://doi.org/10.1182/blood-2015-05-646182 .
doi: 10.1182/blood-2015-05-646182
pubmed: 26261240
pmcid: 4591791
Rakshit S, Sunny JS, George M, Hanna LE, Sarkar K. R-loop modulated epigenetic regulation in T helper cells mechanistically associates coronary artery disease and non-small cell lung cancer. Transl oncol. 2021;14(10):101189. https://doi.org/10.1016/j.tranon.2021.101189 .
doi: 10.1016/j.tranon.2021.101189
pubmed: 34343853
pmcid: 8348198
Rakshit S, Sunny JS, George M, Hanna LE, Leela KV, Sarkar K. T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation bridges link between coronary artery disease and invasive ductal carcinoma. J Cancer Res Clin Oncol. 2022. https://doi.org/10.1007/s00432-022-04130-x .
doi: 10.1007/s00432-022-04130-x
pubmed: 35776197
Huang J, Zhang J, Guo Z, Li C, Tan Z, Wang J, Yang J, Xue L. Easy or not-the advances of EZH2 in regulating T cell development, differentiation, and activation in antitumor immunity. Front Immunol. 2021;12:741302. https://doi.org/10.3389/fimmu.2021.741302 .
doi: 10.3389/fimmu.2021.741302
pubmed: 34737746
pmcid: 8560704
Yu J, Yu J, Rhodes DR, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Can Res. 2007;67(22):10657–63. https://doi.org/10.1158/0008-5472.CAN-07-2498 .
doi: 10.1158/0008-5472.CAN-07-2498
Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate. 2007;67(5):547–56. https://doi.org/10.1002/pros.20550 .
doi: 10.1002/pros.20550
pubmed: 17252556
Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate. 2008;68(3):255–63. https://doi.org/10.1002/pros.20705 .
doi: 10.1002/pros.20705
pubmed: 18095286
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res Fundam Mol Mech Mutagen. 2008;647(1–2):21–9. https://doi.org/10.1016/j.mrfmmm.2008.07.010 .
doi: 10.1016/j.mrfmmm.2008.07.010
Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006;5(16):1886–901. https://doi.org/10.4161/cc.5.16.3222 .
doi: 10.4161/cc.5.16.3222
pubmed: 16963837
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100(20):11606–11. https://doi.org/10.1073/pnas.1933744100 .
doi: 10.1073/pnas.1933744100
pubmed: 14500907
pmcid: 208805
Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97(6):484–91. https://doi.org/10.1111/j.1349-7006.2006.00203.x .
doi: 10.1111/j.1349-7006.2006.00203.x
pubmed: 16734726
Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol. 2010;16(19):2421–7. https://doi.org/10.3748/wjg.v16.i19.2421 .
doi: 10.3748/wjg.v16.i19.2421
pubmed: 20480530
pmcid: 2874149
Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185–97. https://doi.org/10.1016/j.ccr.2010.06.016 .
doi: 10.1016/j.ccr.2010.06.016
pubmed: 20708159
pmcid: 2923653
Smits M, Mir SE, Nilsson RJ, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE. 2011;6(1):e16282. https://doi.org/10.1371/journal.pone.0016282 .
doi: 10.1371/journal.pone.0016282
pubmed: 21297974
pmcid: 3030563
Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013;19(23):6556–65. https://doi.org/10.1158/1078-0432.CCR-12-3946 .
doi: 10.1158/1078-0432.CCR-12-3946
pubmed: 24097870
pmcid: 3890101
Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer. 2010;116(12):3015–24. https://doi.org/10.1002/cncr.25128 .
doi: 10.1002/cncr.25128
pubmed: 20564407
Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011;102(7):1298–305. https://doi.org/10.1111/j/1349-7006.2011.01958x .
doi: 10.1111/j/1349-7006.2011.01958x
pubmed: 21539681
Huqun, Ishikawa R, Zhang J, Miyazawa H, Shimizu Y, Hagiwara K, Koyama N. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer. 2012;118(6):1599–606. https://doi.org/10.1002/cncr.26441 .
doi: 10.1002/cncr.26441
pubmed: 21837672
Cao W, Ribeiro Rde O, Liu D, Saintigny P, Xia R, Xue Y, Lin R, Mao L, Ren H. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS ONE. 2012;7(12):e52984. https://doi.org/10.1371/journal.pone.0052948 .
doi: 10.1371/journal.pone.0052948
pubmed: 23300840
pmcid: 3534094
Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015;34(48):5869–78. https://doi.org/10.1038/onc.2015.38 .
doi: 10.1038/onc.2015.38
pubmed: 25746006
pmcid: 4564363
Li Z, Xu L, Tang N, Xu Y, Shen XYS, Niu X, Lu S, Chen Z. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. FEBS Lett. 2014;588(17):3000–7. https://doi.org/10.1016/j.febslet.2014.05.057 .
doi: 10.1016/j.febslet.2014.05.057
pubmed: 24928441
Wan L, Li X, Shen H, Bai X. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients’ clinical pathological characteristics. Clin Transl Oncol. 2013;15(2):132–8. https://doi.org/10.1007/s12094-0120897-9 .
doi: 10.1007/s12094-0120897-9
pubmed: 22855181
Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene. 2011;30(23):2670–8. https://doi.org/10.1038/onc.2010.635 .
doi: 10.1038/onc.2010.635
pubmed: 21399658
pmcid: 3114186
Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–73. https://doi.org/10.1200/JCO.2005.01.5180 .
doi: 10.1200/JCO.2005.01.5180
pubmed: 16330673
Lv Y, Yuan C, Xiao X, Wang X, Ji X, Yu H, et al. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma. Oncol Rep. 2012;28(1):147–54. https://doi.org/10.3892/or.2012.1787 .
doi: 10.3892/or.2012.1787
pubmed: 22552406
Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9):2613–8. https://doi.org/10.1158/1078-0432.CCR-10-2156 .
doi: 10.1158/1078-0432.CCR-10-2156
pubmed: 21367748
Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080–9. https://doi.org/10.1111/cas.14069 .
doi: 10.1111/cas.14069
pubmed: 31102428
pmcid: 6609813
Zhang Z, Zhou X. Foxp3 instability helps ttregs distinguish self and non-self. Front Immunol. 2019;24(10):2226. https://doi.org/10.3389/fimmu.2019.02226 .
doi: 10.3389/fimmu.2019.02226
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566–78. https://doi.org/10.1016/j.immuni.2011.03.018 .
doi: 10.1016/j.immuni.2011.03.018
pubmed: 21511185
pmcid: 3088485
Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;4(9):847. https://doi.org/10.3389/fimmu.2018.00847 .
doi: 10.3389/fimmu.2018.00847
Li Q, Liu L, Zhang Q, Liu S, Ge D, You Z. Interleukin-17 indirectly promotes M2 macrophage differentiation through stimulation of COX-2/PGE2 pathway in the cancer cells. Cancer Res Treat: Off J Korean Cancer Assoc. 2014;46(3):297–306. https://doi.org/10.4143/crt.2014.46.3.297 .
doi: 10.4143/crt.2014.46.3.297
Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphomath2 cytokines from malignant cells suppress TH1 in L-CTCL. Clin Cancer Res. 2013;19(14):3755–63. https://doi.org/10.1158/1078-0432.CCR-12-3488 .
doi: 10.1158/1078-0432.CCR-12-3488
pubmed: 23785046
pmcid: 3715586
Damalas A, Kahan S, Shtutman M, Ben-Ze’ev A, Oren M. Deregulated β-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 2001;20(17):4912–22. https://doi.org/10.1093/emboj/20.17.4912 .
doi: 10.1093/emboj/20.17.4912
pubmed: 11532955
pmcid: 125598
Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018. https://doi.org/10.1186/s40364-018-0122-2 .
doi: 10.1186/s40364-018-0122-2
pubmed: 29556394
pmcid: 5845366
Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005;280(26):24428–34. https://doi.org/10.1074/jbc.M503790200 .
doi: 10.1074/jbc.M503790200
pubmed: 15870067
Seligson D, Horvath S, Huerta-Yepez S, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27(1):131–41. https://doi.org/10.3892/ijo.27.1.131 .
doi: 10.3892/ijo.27.1.131
pubmed: 15942652
Erkeland SJ, Valkhof M, Heijmans-Antonissen C, et al. The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. Blood. 2003;101(3):1111–7. https://doi.org/10.1182/blood-2002-04-1207 .
doi: 10.1182/blood-2002-04-1207
pubmed: 12393438
de Nigris F, Botti C, de Chiara A, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006;42(15):2420–4. https://doi.org/10.1016/j.ejca.2006.06.008 .
doi: 10.1016/j.ejca.2006.06.008
pubmed: 16962318
de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1- integrin in tumour cells. Oncogene. 2007;26(3):382–94. https://doi.org/10.1038/sj.onc.1209804 .
doi: 10.1038/sj.onc.1209804
pubmed: 16878156
Baritaki S, Chatzinikola AM, Vakis AF, et al. YY1 over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest. 2009;27(2):184–92. https://doi.org/10.1080/07357900802210760 .
doi: 10.1080/07357900802210760
pubmed: 19235591
Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686–96. https://doi.org/10.1158/1078-0432.CCR-04-2398 .
doi: 10.1158/1078-0432.CCR-04-2398
pubmed: 15897565
Sakhinia E, Glennie C, Hoyland JA, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood. 2007;109(9):3922–8. https://doi.org/10.1182/blood-2006-09-046391 .
doi: 10.1182/blood-2006-09-046391
pubmed: 17255358
Chinnappan D, Xiao D, Ratnasari A, Andry C, King TC, Weber HC. Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol. 2009;34(5):1417–23. https://doi.org/10.3892/ijo_00000270 .
doi: 10.3892/ijo_00000270
pubmed: 19360355
Zhang JJ, Zhu Y, Yang C, Liu X, Peng YP, Jiang KR, et al. Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Oncotarget. 2016;7(19):28498–509. https://doi.org/10.18632/oncotarget.8654 .
doi: 10.18632/oncotarget.8654
pubmed: 27074573
pmcid: 5053741
de Nigris F, Rossiello R, Schiano C, et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Can Res. 2008;68(6):1797–808. https://doi.org/10.1158/0008-5472.CAN-07-5582 .
doi: 10.1158/0008-5472.CAN-07-5582
Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27(15):2503–8. https://doi.org/10.1200/JCO.2008.17.9762 .
doi: 10.1200/JCO.2008.17.9762
pubmed: 19332734
Zhang Y, Sun Z, Fu T, Liu C, Liu Y, Lin Y. The microRNA-635 suppresses tumorigenesis in non-small cell lung cancer. Biomed Pharmacother. 2016;84:1274–81. https://doi.org/10.1016/j.biopha.2016.10.040 .
doi: 10.1016/j.biopha.2016.10.040
pubmed: 27810784
Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle. 2010;9(3):512–22. https://doi.org/10.4161/cc.9.3.10588 .
doi: 10.4161/cc.9.3.10588
pubmed: 20081375
Huang T, Wang G, Yang L, Peng B, Wen Y, Ding G, Wang Z. Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1. DNA Cell Biol. 2017;36(11):1–12. https://doi.org/10.1089/dna.2017.3857 .
doi: 10.1089/dna.2017.3857
Au SL, Wong CC, Lee JM, Wong C, Ng IO. EZH2-mediated H3K27me3 is involved in epigenetic repression of deleted in liver cancer 1 in human cancers. PLoS ONE. 2013;8(6):e68226.
doi: 10.1371/journal.pone.0068226
pubmed: 23826380
pmcid: 3694912
Xu C, Hou Z, Zhan P, Zhao W, Chang C, Zou J, Hu H, Zhang Y, Yao X, Yu L, et al. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med Oncol. 2013;30(4):713. https://doi.org/10.1007/s12032-013-0713-6 .
doi: 10.1007/s12032-013-0713-6
pubmed: 24132606
Zhang YB, Niu HT, Chang JW, Dong GL, Ma XB. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Eur J Cancer Care. 2010;20(1):106–12. https://doi.org/10.1111/j.1356-2354.2009.01148x .
doi: 10.1111/j.1356-2354.2009.01148x
de Vries NA, Hulsman D, Akhtar W, et al. Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Report. 2015;10(3):383–97. https://doi.org/10.1016/j.celrep.2014.12.028 .
doi: 10.1016/j.celrep.2014.12.028
Wu GQ, et al. Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1. Oncotarget. 2016;7(18):26535–50. https://doi.org/10.18632/oncotarget.8532 .
doi: 10.18632/oncotarget.8532
pubmed: 27049834
pmcid: 5041997
Tumes DJ, et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity. 2013;39(5):819–32. https://doi.org/10.1016/j.immuni.2013.09.012 .
doi: 10.1016/j.immuni.2013.09.012
pubmed: 24238339
Sui G. The regulation of YY1 in tumorigenesis and its targeting potential in cancer therapy. Mol Cell Pharmacol. 2009;1(13):157–76. https://doi.org/10.4255/mcpharmacol.09.20 .
doi: 10.4255/mcpharmacol.09.20
Pan X, Papasani M, Hao Y, et al. YY1 controls Igκ repertoire and B-cell development, and localizes with condensin on the Igκ locus. EMBO J. 2013;32(8):1168–82. https://doi.org/10.1038/emboj.2013.66 .
doi: 10.1038/emboj.2013.66
pubmed: 23531880
pmcid: 3630362
Basu A, Wilkinson FH, Colavita K, et al. YY1 DNA binding and interaction with YAF2 is essential for polycomb recruitment. Nucleic Acids Res. 2014;42(4):2208–23. https://doi.org/10.1093/nar/gkt1187 .
doi: 10.1093/nar/gkt1187
pubmed: 24285299
Tsang DPF, et al. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma. J Pathol. 2016;238(5):651–64. https://doi.org/10.1002/path.4688 .
doi: 10.1002/path.4688
pubmed: 26800240
Ghosh T, Barik S, Bhuniya A, Dhar J, Dasgupta S, Ghosh S, Sarkar M, Guha I, Sarkar K, Chakrabarti P, Saha B. Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells. Int J Cancer. 2016;139(9):2068–81. https://doi.org/10.1002/ijc.30265 .
doi: 10.1002/ijc.30265
pubmed: 27405489
Obradovic J, Todosijevic J, Jurisic V. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Mol Biol Rep. 2021;48(4):3593–604. https://doi.org/10.1007/s11033-021-06379-w .
doi: 10.1007/s11033-021-06379-w
pubmed: 33973139
Obradovic J, Todosijevic J, Jurisic V. Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: a systematic review and meta-analysis. Oncol Lett. 2022;25(2):62. https://doi.org/10.3892/ol.2022.13649 .
doi: 10.3892/ol.2022.13649
pubmed: 36644136
pmcid: 9827468
Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjević N. EGFR polymorphism and survival of NSCLC patients treated with TKIs: a systematic review and meta-analysis. J oncol. 2020;2020:1973241. https://doi.org/10.1155/2020/1973241 .
doi: 10.1155/2020/1973241
pubmed: 32256580
pmcid: 7104312
Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 2020;17(9):663–74. https://doi.org/10.1080/14789450.2020.1845654 .
doi: 10.1080/14789450.2020.1845654
pubmed: 33131355
Konjević GM, Vuletić AM, Mirjačić Martinović KM, Larsen AK, Jurišić VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30–40. https://doi.org/10.1016/j.cyto.2019.02.001 .
doi: 10.1016/j.cyto.2019.02.001
pubmed: 30784898
Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:115–24. https://doi.org/10.1007/978-94-017-7215-0_8 .
doi: 10.1007/978-94-017-7215-0_8
pubmed: 26530363
Konjević G, Jurisić V, Spuzić I. Corrections to the original lactate dehydrogenase (LDH) release assay for the evaluation of NK cell cytotoxicity. J Immunol Methods. 1997;200(1–2):199–201. https://doi.org/10.1016/s0022-1759(96)00194-9 .
doi: 10.1016/s0022-1759(96)00194-9
pubmed: 9005959